Products Reteplase was marketed as an injectable (Rapilysin). The drug was approved in many countries in 1996 and withdrawn from the market in 2013. Structure and properties Reteplase is derivative of tissue-specific plasminogen activator (t-PA). It is a serine protease containing 355 of the 527 amino acids of native t-PA. The protein is produced by … Reteplase
Products Streptokinase was commercially available as an injectable in many countries (Streptase, off label). It is still available in other countries. Structure and properties Streptokinase is a protein derived from group C hemolytic streptococci. Effects Streptokinase (ATC B01AD01) has fibrinolytic and thrombolytic properties. It combines with plasminogen to form a streptokinase-plasminogen complex. This complex converts … Streptokinase
Products Alteplase is commercially available as an injectable (Actilyse). The drug has been approved in many countries since 1988. Structure and properties Alteplase is a recombinant tissue plasminogen activator (rt-PA) produced by biotechnological methods. It is a serine protease composed of 527 amino acids. Effects Alteplase (ATC B01AD02) has fibrinolytic and thrombolytic properties. The enzyme … Alteplase
Products Urokinase is commercially available as a powder for the preparation of a solution for injection or infusion (Urokinase HS medac). The drug has been approved in many countries since 1988. Structure and properties Urokinase is a serine protease, which is extracted from human urine in China. It is also possible to produce it using … Urokinase
Products Tenecteplase is commercially available as an injectable (metalysis). The drug has been approved in many countries since 2000. Structure and properties Tenecteplase is a recombinant fibrin-specific plasminogen activator produced by biotechnological methods. The glycoprotein consists of 527 amino acids. The sequence is modified from native tissue-specific plasminogen activator (t-PA) at three sites. Effects Tenecteplase … Tenecteplase
